Mapping the Functional Assessment of Cancer Therapy - Breast (FACT-B) to the 5-level EuroQoL group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a Multi-ethnic Asian population by Cheung, Yin Bun et al.
 
 
This document has been downloaded from  
TamPub – The Institutional Repository of University of Tampere 
 
 
Publisher's version 
 
The permanent address of the publication http://urn.fi/URN:NBN:fi:uta-
201412222510  
  
Author(s):  Cheung, Yin; Luo, Nan; Ng, Raymond; Lee, Chung 
Title:  
Mapping the Functional Assessment of Cancer Therapy - Breast 
(FACT-B) to the 5-level EuroQoL group’s 5-dimension questionnaire 
(EQ-5D-5L) utility index in a Multi-ethnic Asian population 
Year:  2014 
Journal 
Title:  Health and Quality of Life Outcomes 
Vol and 
number:  12 : 1  
Pages:  180 
ISSN:  1477-7525 
Discipline:  Biomedicine; Cancers 
School 
/Other Unit:  School of Medicine 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/10.1186/s12955-014-0180-6  
URN:  URN:NBN:fi:uta-201412222510 
URL:  http://www.hqlo.com/content/12/1/180 
 
  
 
 
All material supplied via TamPub is protected by copyright and other intellectual 
property rights, and duplication or sale of all part of any of the repository collections 
is not permitted, except that material may be duplicated by you for your research use 
or educational purposes in electronic or print form. You must obtain permission for 
any other use. Electronic or print copies may not be offered, whether for sale or 
otherwise to anyone who is not an authorized user. 
Cheung et al. Health and Quality of Life Outcomes 2014, 12:180
http://www.hqlo.com/content/12/1/180RESEARCH Open AccessMapping the Functional Assessment of Cancer
Therapy - Breast (FACT-B) to the 5-level EuroQoL
group’s 5-dimension questionnaire (EQ-5D-5L)
utility index in a Multi-ethnic Asian population
Yin Bun Cheung1,2,3, Nan Luo4, Raymond Ng5 and Chun Fan Lee1,2*Abstract
Purpose: To develop an algorithm for mapping the Functional Assessment of Cancer Therapy – Breast (FACT-B) to
the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index.
Methods: A survey of 238 breast cancer patients in Singapore was conducted. Models using various regression
methods with or without recognizing the upper boundary of utility values at 1 were fitted to predict the EQ-5D-5L
utility index based on the five subscale scores of the FACT-B. Data from a follow-up survey of these patients were
used to validate the results.
Results: A model that maps the physical, emotional, functional well-being and the breast cancer concerns subscales
of the FACT-B to the EQ-5D-5L utility index was derived. The social well-being subscale was not associated to the
utility index. Although theoretical assumptions may not be valid, ordinary least square outperformed other regression
methods. The mean predicted utility index within each performance status level at follow-up deviated from the
observed mean less than the minimally important difference of EQ-5D for cancer patients.
Conclusions: The mapping algorithm converts the FACT-B to the EQ-5D utility index. This enables oncologists, clinical
researchers and policy makers to obtain a quantitative utility summary of a patient’s health status when only the FACT-B
is assessed.
Keywords: Breast cancer, EQ-5D-5L, FACT-B, Health utility, Mapping, Quality of lifeIntroduction
The EuroQoL Group’s 5-dimension questionnaire (EQ-5D)
is a generic, preference-based instrument that measures re-
spondents’ health status using a utility index. This interval-
type utility index indicates the value of various specific
health states using standardized valuation methods such
as time trade-off or standard gamble, and is essential in
health economic evaluation like cost-utility and quality-
adjusted life-year analyses. The EQ-5D is preferred by
health technology assessment organisations such as the
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unless otherwise stated.United Kingdom, for eliciting health utility values (http://
www.nice.org.uk, accessed 6 March 2014). However,
preference-based measures are not always used in clinical
studies. Most disease-specific instruments are profile-
based and only provide ordinal-level measurement scales
that cannot be used for health economic analysis. One so-
lution to utilize non-preference-based instruments to per-
form economic evaluation is to map such measures to the
EQ-5D utility index. The NICE has released guidelines
and technical support documents to guide the selection
and use of mapping algorithms to EQ-5D [1-3]. Since
then, there was a substantial increase in the number of
studies reporting mapping algorithms to EQ-5D, from one
study per year between 2000 and 2003 to 17 studies per
year in 2012 and 2013 [4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(FACIT) Measurement System is a collection of health-
related quality-of-life (HRQoL) questionnaires for vari-
ous chronic diseases [5,6]. The core component of the
FACIT system is the Functional Assessment of Cancer
Therapy – General (FACT-G) for patients of any cancer
type. This 27-item instrument can also be extended to a
more specific instrument by adding a cancer type spe-
cific module. For example, the FACT-G becomes the
FACT-Breast (FACT-B) if a 10-item breast cancer-
specific module is added. Studies that map the scores of
the FACT instruments to the EQ-5D utility index are
not rare. Examples include the mapping of FACT-G [7],
FACT-Prostate [8] and FACT-Melanoma [9] to the
EQ-5D utility index. However, there is no available map-
ping algorithm in the literature to convert the FACT-B to
EQ-5D. Breast cancer has been reported in the Global
Cancer Statistics 2011 as the most common type of cancer
among women worldwide [10]. In 2008, 1.38 million
women were diagnosed of breast cancer accounting for
23% of the total new cancer cases. The purpose of the
current study is to formulate a mapping algorithm for gen-
erating the EQ-5D health utility index from the FACT-B,
so that oncologists and clinical researchers can obtain
both a psychometric description and a quantitative utility
summary of a patient’s health status from a single assess-
ment using the FACT-B, without imposing additional as-
sessment burden on patients.
Methods
Design and recruitment
This is a secondary analysis of a study that aimed to
evaluate the measurement properties of the English and
Chinese versions of two instruments, namely the FACT-
B and the 5-level EQ-5D (EQ-5D-5L), in breast cancer
patients in Singapore [11]. The study was approved by
the Singapore Health Services Institutional Review Board.
Inpatients were recruited from the oncology wards of the
Singapore General Hospital while outpatients from the
specialist outpatient clinics of the National Cancer Centre,
Singapore. Patients who aged 21 years or above, were his-
tologically confirmed breast cancer, able to understand
Chinese or English or both, with no evidence of brain me-
tastasis, psychosis or severe depression, and willing to give
written informed consent were recruited. They chose to
answer either a Chinese or an English questionnaire pack-
age according to their preference. Each package included
the EQ-5D-5L and FACT-B, together with some questions
on demographics and performance status. Approximately
one week after the baseline assessment, the patients were
sent a similar package with a postage-paid return enve-
lope enclosed to evaluate their HRQoL, health utility and
performance status for assessment of test-retest reliability
of the instruments. Up to two reminders with thequestionnaire package were sent at two-weekly intervals
if the package was not returned. Other clinical informa-
tion was provided by the patients’ treating oncologists. At
baseline, the questionnaire package was self-administered
by the patients, or by a research assistant upon patient’s
request. At follow-up, it was self-administered by the pa-
tients. Questionnaires not self-administered were excluded
from this analysis.
Instruments and variables
The FACT-B is a breast cancer-specific HRQoL instru-
ment of the FACIT system. The 37-item English and
(simplified) Chinese FACT-B version 4 are divided into
five subscales, namely physical (PWB), social/family (SWB),
emotional (EWB), functional well-beings (FWB), and the
additional concerns for breast cancer (BCS) [12,13]. We
have reported the validity and reliability of, and the com-
parability between the two language versions in an earlier
study [14]. Each item is rated on a 5-point Likert scale.
Negatively worded items were recoded such that a higher
score indicates a better HRQoL. The FACT-B total score
is the sum of scores of all five subscales, the FACT-G
score is the sum of PWB, SWB, EWB and FWB, while
the Trial Outcome Index (TOI) is the sum of scores of
the PWB, FWB and BCS. Missing values were imputed
as the mean of observed items provided more than half
of the items comprising a subscale were answered, i.e.
the “half-rule” [5].
The EQ-5D-5L contains five questions (mobility, self-
care, usual activities, pain/discomfort, and anxiety/de-
pression), plus a vertical, 0-100-point visual analogue
scale for rating the overall health status. Respondents
could choose one of the five levels to describe their
health state on the day of survey. These five levels in-
clude “no problem”, “slight problems”, “moderate prob-
lems” and “severe problems” in all five dimensions, and
“unable” in mobility, self-care and usual activities or “ex-
treme problems” in pain/discomfort and anxiety/depres-
sion [15]. In this study, experimental English and Chinese
versions of the EQ-5D-5L were used because the official
version was not available at the time. The differences be-
tween the official and experimental versions are minor
[16]. In the official English version the responses start with
“I have” or “I am,” which are omitted in the experimental
English version. For the self-care dimension, the official
Chinese version asks the degree of problems in “washing
and dressing” while the experimental Chinese version asks
about “combing, washing and dressing.” Other differences
in Chinese version only involve the use of some words
which are actually synonyms and commonly used in daily
life, e.g., the English word “usual” is translated to “ri
chang” (in Chinese phonetic transcription here) in the offi-
cial Chinese version and “pin chang” in the experimental
version. Recently, we reported the validity and reliability
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versions of the EQ-5D-5L [16].
The answers to the same five questions in an older 3-
level version, EQ-5D-3 L, can be converted to a utility
index through some country-specific value set. For the
conversion of the EQ-5D-5L to a utility index, however, an
official value set has not been released by the EuroQoL
Group at the time of writing this report. Instead, a cross-
walk project converting the EQ-5D-3 L value set to the
EQ-5D-5L was conducted by the EuroQoL Group which
resulted in the interim value sets [17]. We obtained and
used the Japanese value set (Dr. Rosalind Rabin, the
EuroQoL Group), the only Asian value set available in
the crosswalk project. Using this value set, the EQ-5D-5L
utility index has a possible range of −0.111 to 1 [18]. As a
sensitivity analysis, the UK value with possible range
of −0.594 to 1 was also employed. A higher index means
a better health state, with 1, 0, positive values between 1
and 0, and negative values corresponding to full health,
death, health states better than death but worse than full
health, and health states worse than death, respectively.
The performance status is known to be strongly asso-
ciated with patients’ quality of life [19], and can be
assessed by both the oncologists and the patients them-
selves [20]. Respondents choose the most appropriate
one that describes the cancer patient from five options
ranging from 0 (without symptoms) to 4 (bedridden)
[21]. The score of 5 (death) was not applicable in this
study.
Statistical analysis
The baseline survey was used for developing the mapping
functions. The EQ-5D-5L utility index was regressed on a
combination of the five subscales of the FACT-B. Five dif-
ferent models were examined. Model 1 included all five
subscales of the FACT-B, Model 2 the four subscales of
the FACT-G, and Model 3 the three subscales of the TOI.
Based on some preliminary analysis, the coefficients of the
SWB subscale in Models 1 and 2 were found to be insig-
nificant and small in magnitude, and in some cases nega-
tive. Therefore, two more models (Models 4 and 5) were
conducted by dropping the SWB subscale. Since equiva-
lence between English and Chinese versions of the two in-
struments could not be surely confirmed in the previous
studies [14,16], we also conducted some sensitivity ana-
lyses by fitting models that included language as well as
interactions between language and the subscales as predic-
tors to investigate whether it should be included in the
mapping algorithm.
The EQ-5D-5L utility index is bounded from above by
1 which indicates full health. Previous studies pointed
out that this upper bound may invalidate the normality
assumption of ordinary least square (OLS) method. Tobit
model, an alternative to OLS to deal with censored data,has been suggested for use in mapping. However, it is in-
consistent to the presence of heteroscedasticity [22,23].
Censored least absolute deviations (CLAD) is a solution to
the heteroscedasticity problem in the Tobit model [24].
This has also been used in the current context. However,
an upper bound is not the same as a censoring threshold.
Thus, apart from OLS, Tobit and CLAD models, we also
considered two regression methods, namely quantile re-
gression and logistic quantile regression [25,26]. Quantile
regression is also called median regression if the second
quantile, i.e. median, is fitted (as in this study) [25]. The
difference between CLAD and median regression is that
the former assumes the dependent variable is a censored
value of some unobserved latent variable, while the latter
does not. In other words, CLAD is a censored version of
median regression. Logistic quantile regression is an ap-
proach for handling bounded outcomes [26], which is the-
oretically correct for mapping of utility values. Suppose
the outcome y is bounded from below and from above by
two known constants, ymin and ymax, respectively. A logis-
tic transform is applied to the outcome to obtain
h yð Þ ¼ log y−ymin
ymax−y
 
;
and a quantile regression is then fitted by regressing the
transformed outcome h(y) on the independent variables.
In practice, to ensure the logistic transform is defined for
all observed values, ymin is set to be slightly smaller than
the smallest observed outcome, and ymax slightly larger
than the largest observed outcome. In this study, we set
ymin = 0.17885 for Japanese value set and −0.28265 for UK
value set (i.e. half of the observed smallest increment less
than the smallest observed utility value from the respect-
ive value set [27]), and ymax = 1.001 for both value sets.
The visual analogue scale of the EQ-5D was not used in
the analysis.
Model performance was examined by several goodness-
of-fit measures. The coefficient of determination, R2, in
OLS may not be well-defined in other regression methods.
The pseudo-R2, an alternative to R2 defined by the likeli-
hood ratio between the intercept-only model and the full
model, is not comparable across different regression
methods [28]. Instead, we computed the square of the cor-
relation coefficient (r) between the observed and predicted
values from each model. Note that R2 is equivalent to r2 in
OLS. Parallel to OLS, to penalize for the complexity of the
model, we considered an adjusted r2 defined as
adjusted r2 ¼ 1 – n – 1ð Þ
n – p – 1ð Þ 1 – r
2
 
;
where n is the sample size and p is the number of pa-
rameters in the model. Goodness-of-fit was also exam-
ined by mean square error (MSE) and mean absolute
Table 1 Demographic and baseline information of 238
eligible subjects
Characteristics N (%)
Age (year), Mean (standard deviation) 51.3 (9.7)
Language of questionnaire
English 160 (67.2)
Chinese 78 (32.8)
Race
Chinese 193 (81.1)
Malay 23 (9.7)
Indian 18 (7.6)
Others 4 (1.7)
Marital status
Married 168 (70.9)
Single 47 (19.8)
Divorced/separated 12 (5.1)
Widowed 10 (4.2)
Education level
Primary or below 48 (20.3)
Secondary 112 (47.3)
Postsecondary 77 (32.5)
Inpatient/Outpatient
Inpatient 70 (29.4)
Outpatient 168 (70.6)
Patient-assessed performance status
0 97 (40.8)
1 115 (48.3)
2 17 (7.1)
3 or 4 9 (3.8)
Evidence of disease
Present 118 (50.0)
Absent 118 (50.0)
Purpose of visit
Treatment – Adjuvant/curative/hormone therapy 112 (47.7)
Treatment – Palliative 78 (33.2)
No treatment – Follow-up 45 (19.1)
On chemotherapy/radiotherapy
Yes 100 (42.0)
No 138 (58.0)
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squared deviations whereas CLAD and quantile regres-
sion minimize the sum of absolute deviations, one would
expect that the MSE tends to favor the OLS while MAD
tends to favor the CLAD and quantile regression. There-
fore, the interpretation should not focus exclusively on
one index. The distributions of the observed and mapped
utility values were also compared. The follow-up survey
was used for validating the resulted algorithms. The dif-
ferences between the observed and predicted utility
values at follow-up were tested by signed-rank tests
within each performance status level. All statistical ana-
lyses were performed in SAS system version 9.3 (SAS
Institute, Cary, NC, USA) and Stata version 10 (StatCrop,
College Station, TX).
Results
Two hundred and eighty female breast cancer patients
consented to participate and answered the questionnaire
package. At baseline, 39 patients did not self-administer
the questionnaire package and were thus removed from
the analysis. Three patients were further excluded due to
missing values in the EQ-5D-5L or FACT-B beyond im-
putation by the half-rule. As a result, 238 patients at
baseline were used in the development sample. Their
demographic and clinical information at baseline is sum-
marized in Table 1. Most of the patients answered an
English package (67.2%), were ethnic Chinese (81.1%),
married (70.9%) and outpatients (70.6%). Among them,
221 returned the questionnaire package with no missing
values, and were used for validation.
Table 2 describes the distributions of the EQ-5D-5L
utility index and the FACT-B total and subscale scores
of the sample at baseline and follow-up. There were ap-
proximately a quarter of patients reporting full EQ-5D-5L
utility value at baseline and one fifth at follow-up. No pa-
tient reported a maximum FACT-B total score at both
time points, but the FACT-G score and four subscales
(PWB, SWB, EWB and FWB) reached the upper bound in
some patients. For the BCS subscale, one patient had max-
imum score at baseline, but none at follow-up.
The results of the regression analyses using the Japanese
value set are displayed in Table 3. For each regression
method, five models were fitted. Among the five models,
Model 4 consisting of the PWB, EWB, FWB and BCS had
the largest adjusted r2, regardless of the regression method
used. The MSE and MAD of the five models were similar,
but mostly Model 4 had the smallest, with the only excep-
tion in the MAD (0.0913) which was marginally larger
than that of Model 1 (0.0912) for CLAD and quantile
regression. Among the five regression methods, OLS
generally had the largest adjusted r2 (0.4782 to 0.4887)
and smallest MSE (0.0132 to 0.0135) and MAD (0.0913
to 0.0925), followed by CLAD and quantile regression(adjusted r2 ranged from 0.4775 to 0.4882; MSE from
0.0133 to 0.0135; MAD from 0.0912 to 0.0923). The latter
two had the same point estimates for the regression coeffi-
cients in all models. However, due to different model as-
sumption and estimation process, their standard errors
were not the same (details not shown), and hence the
p-values were different.
Table 2 Distribution of EQ-5D-5L and FACT-B scores and subscales at baseline and follow-up
Observed Scores Mean SD Min Q1 Median Q3 Max Lower bound Upper bound
Baseline (N = 238)
EQ-5D-5L utility index
Japanese value set 0.777 0.163 0.179 0.686 0.740 0.843 1.000 0 (0.0%) 59 (24.8%)
UK value set 0.785 0.200 −0.283 0.721 0.777 0.906 1.000 0 (0.0%) 59 (24.8%)
FACT-B
Total score 103.0 20.8 45 90 104 119 140 0 (0.0%) 0 (0.0%)
FACT-G score 81.3 16.9 35 71 83 95 108 0 (0.0%) 4 (1.7%)
Trial outcome index 62.8 14.9 16 53 64 74 89 0 (0.0%) 0 (0.0%)
Physical well-being 21.1 6.0 1 18 22 26 28 0 (0.0%) 29 (12.2%)
Social well-being 22.2 6.1 0 20 24 27 28 3 (1.3%) 50 (21.0%)
Emotional well-being 18.0 4.7 4 15 19 22 24 0 (0.0%) 28 (11.8%)
Functional well-being 20.0 6.7 0 16 21 26 28 3 (1.3%) 31 (13.0%)
Breast cancer subscale 21.7 6.1 5 17 22 27 36 0 (0.0%) 1 (0.4%)
Follow-up (N = 221)
EQ-5D-5L utility index
Japanese value set 0.758 0.160 0.052 0.649 0.740 0.829 1.000 0 (0.0%) 46 (20.8%)
UK value set 0.770 0.193 −0.283 0.679 0.768 0.879 1.000 0 (0.0%) 46 (20.8%)
FACT-B
Total score 101.2 22.2 27 85 103 118 140 0 (0.0%) 0 (0.0%)
FACT-G score 79.6 18.0 20 67 82 94 108 0 (0.0%) 5 (2.3%)
Trial outcome index 61.6 15.8 9 51 63 74 89 0 (0.0%) 0 (0.0%)
Physical well-being 21.0 6.1 0 17 22 26 28 2 (0.9%) 26 (11.8%)
Social well-being 21.7 5.5 4 18 22 27 28 0 (0.0%) 40 (18.1%)
Emotional well-being 17.9 4.7 3 15 19 21 24 0 (0.0%) 25 (11.3%)
Functional well-being 19.0 6.9 2 14 21 25 28 0 (0.0%) 20 (9.0%)
Breast cancer subscale 21.6 6.2 7 17 22 26 35 0 (0.0%) 0 (0.0%)
Abbreviations: SD standard deviation, Min minimum, Q1 1st quartile, Q3 third quartile, Max maximum.
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teractions between language and the subscales as predic-
tors, the coefficient estimates were small in magnitude
and insignificant. Moreover, adding language into the
model did not improve the goodness-of-fit nor alter
qualitatively the parameter estimates of other variables.
Models with interaction and quadratic terms of the sub-
scales were also fitted. However, these terms were insig-
nificant and did not improve the model in terms of
goodness-of-fit (details not shown). Moreover, the re-
sults using the UK value set were similar to that of the
Japanese value set, hence were not shown here either.
One point worth noting is that CLAD and quantile re-
gression had different point estimates when the UK
value set was used.
The observed and predicted EQ-5D-5L utility index
values by Models 3 through 5 at baseline survey were com-
pared (Table 4). For central tendency, the five methods
performed differently. As restricted by the estimationprocess, the means of the predicted values based on OLS
were always the same as that of the observed values; but
the median of the predicted values were larger than that of
the observed ones. The Tobit models tended to produce
larger predicted values than the observed ones, hence
resulting in larger means and medians. CLAD, quantile re-
gression and logistic quantile regression had the mean
predicted values slightly smaller than the observed mean,
but the medians were also larger than the observed me-
dian. For dispersion, however, predicted values by all
methods had a smaller spread than the observed values.
Compared with the observed values, the predicted
values by each model had a smaller standard deviation,
larger minimum and 10th percentile but smaller 90th
percentile and maximum. It was possible that the pre-
dicted EQ-5D-5L utility index fell outside the defined
range of −0.111 to 1 (for Japanese value set). However,
this only happened in less than 3% of the sample in
Models 3 and 4 when the Tobit method was used.
Table 3 Coefficient estimates and goodness-of-fit measures of various regression models mapping the FACT-B subscales
to EQ-5D-5L utility index based on baseline survey (N = 238)
Model 1 Model 2 Model 3 Model 4 Model 5
Ordinary least square
Regression coefficients
Constant 0.2901** 0.3071** 0.3064** 0.2846** 0.3031**
Physical well-being 0.0120** 0.0127** 0.0125** 0.0121** 0.0128**
Social well-being −0.0003 −0.0003
Emotional well-being 0.0042* 0.0062** 0.0041 0.0061**
Functional well-being 0.0046** 0.0048** 0.0052** 0.0044** 0.0046**
Breast cancer subscale 0.0035* 0.0048** 0.0034*
Goodness-of-fit measures
Square of correlation coefficient, r2 0.4975 0.4870 0.4890 0.4973 0.4870
Adjusted r2 0.4867 0.4782 0.4824 0.4887 0.4804
Mean square error 0.0132 0.0135 0.0135 0.0132 0.0135
Mean absolute deviation 0.0913 0.0918 0.0925 0.0913 0.0919
Tobit model
Regression coefficients
Constant 0.1983** 0.2200** 0.2342** 0.2077** 0.2318**
Physical well-being 0.0144** 0.0153** 0.0147** 0.0142** 0.0152**
Social well-being 0.0006 0.0007
Emotional well-being 0.0050 0.0077** 0.0051 0.0078**
Functional well-being 0.0048* 0.0051** 0.0060** 0.0051** 0.0054**
Breast cancer subscale 0.0045* 0.0063** 0.0046*
Goodness-of-fit measures
Square of correlation coefficient, r2 0.4965 0.4861 0.4887 0.4971 0.4869
Adjusted r2 0.4856 0.4773 0.4821 0.4885 0.4803
Mean square error 0.0143 0.0146 0.0145 0.0143 0.0145
Mean absolute deviation 0.0934 0.0937 0.0945 0.0934 0.0936
Censored least absolute deviation
Regression coefficients
Constant 0.3062** 0.3208** 0.3200** 0.2948** 0.3149**
Physical well-being 0.0119** 0.0121** 0.0123** 0.0122** 0.0121**
Social well-being −0.0004 −0.0003
Emotional well-being 0.0041 0.0054** 0.0042 0.0054**
Functional well-being 0.0037* 0.0054** 0.0039* 0.0037* 0.0053**
Breast cancer subscale 0.0036 0.0054** 0.0035
Goodness-of-fit measures
Square of correlation coefficient, r2 0.4968 0.4863 0.4873 0.4968 0.4862
Adjusted r2 0.4860 0.4775 0.4807 0.4882 0.4796
Mean square error 0.0133 0.0135 0.0135 0.0133 0.0135
Mean absolute deviation 0.0912 0.0917 0.0923 0.0913 0.0917
Model 1 Model 2 Model 3 Model 4 Model 5
Quantile regression
Regression coefficients
Constant 0.3062** 0.3208** 0.3200** 0.2948** 0.3149**
Physical well-being 0.0119** 0.0121** 0.0123** 0.0122** 0.0121**
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Table 3 Coefficient estimates and goodness-of-fit measures of various regression models mapping the FACT-B subscales
to EQ-5D-5L utility index based on baseline survey (N = 238) (Continued)
Social well-being −0.0004 −0.0003
Emotional well-being 0.0041 0.0054** 0.0042* 0.0054**
Functional well-being 0.0037** 0.0054** 0.0039** 0.0037** 0.0053**
Breast cancer subscale 0.0036 0.0054** 0.0035
Goodness-of-fit measures
Square of correlation coefficient, r2 0.4968 0.4863 0.4873 0.4968 0.4862
Adjusted r2 0.4860 0.4775 0.4807 0.4882 0.4796
Mean square error 0.0133 0.0135 0.0135 0.0133 0.0135
Mean absolute deviation 0.0912 0.0917 0.0923 0.0913 0.0917
Logistic quantile regression
Regression coefficients
Constant −1.6525 −1.6097 −1.5750* −1.6489 −1.6678
Physical well-being 0.0684 0.0710 0.0678* 0.0683** 0.0722**
Social well-being 0.0001 −0.0035
Emotional well-being 0.0155 0.0320 0.0157 0.0308
Functional well-being 0.0230 0.0312 0.0247 0.0230 0.0295
Breast cancer subscale 0.0216 0.0301 0.0214
Goodness-of-fit measures
Square of correlation coefficient, r2 0.4686 0.4596 0.4620 0.4687 0.4597
Adjusted r2 0.4571 0.4503 0.4551 0.4596 0.4528
Mean square error 0.0141 0.0143 0.0143 0.0141 0.0143
Mean absolute deviation 0.0946 0.0949 0.0953 0.0946 0.0950
**P-value < 0.01; *P-value < 0.05.
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EQ-5D-5L utility index by Models 3 through 5 classified
by performance status at follow-up. The utility index
was significantly overestimated in the group with per-
formance status of 1, but underestimated in the group
with performance status of 0 only when the logistic
quantile regression was used. The largest differences be-
tween observed and predicted values were approximately
0.06. The predicted utility index showed significantly de-
creasing trend with performance status (all p-values for
trend < 0.001).
Discussion
The regression analyses showed that the EQ-5D-5L
index of the breast cancer patients in our sample was
best predicted by the model consisting of four FACT-B
subscales, i.e., PWB, EWB, FWB and BCS (Model 4). Al-
though the coefficients of BCS and EWB were respect-
ively significant in Model 3 and Model 5 for most
regression methods, they were not both significant in
Model 4. However, this study aimed to construct a
model that best predicts the utility index, so whether the
regression coefficients are statistically significant is of
secondary consideration. The most important criterionis the accuracy of the prediction. The observed and pre-
dicted values correlated more closely in Model 4 than in
Models 3 and 5 even after penalizing for model com-
plexity, and the MSE and MAD were the smallest in
Model 4. Although BCS contains several emotion-
related items, those items are more specific to breast
cancer patients than those in the EWB subscales, e.g., “I
feel sexually attractive,” “I am able to feel like a woman”,
etc. Therefore, it is appropriate to include both BCS and
EWB in the model. On the other hand, due to a lack of
social-related item in the EQ-5D-5L, SWB was not asso-
ciated with the utility index. In the current study and
two previous mapping studies of FACT-G and FACT-
Prostate, the coefficient for SWB was negative despite be-
ing insignificant [7,8]. Although this is counter-intuitive as
one would not expect that better social well-being leads to
lower health utility, it is possible that patients in declining
health perceive social-related quality-of-life more posi-
tively than those in better health.
In this study, OLS had the best goodness-of-fit while
the performance of CLAD and quantile regression were
close to OLS, but Tobit model and logistic quantile re-
gression did not perform well. Previous studies showed
that CLAD and OLS were superior to Tobit model in
Table 4 Descriptive summary of the baseline EQ-5D-5L utility index derived from observed data and regression models
Model Mean SD Min P10 Q1 Median Q3 P90 Max Upper bound
Observed data 0.7772 0.1626 0.1789 0.6079 0.6856 0.7402 0.8428 1.0000 1.0000 24.8%
Ordinary least square
Model 3 0.7772 0.1137 0.3930 0.6162 0.7059 0.7902 0.8643 0.9150 0.9583 0%
Model 4 0.7772 0.1147 0.3830 0.6149 0.7082 0.7898 0.8648 0.9146 0.9498 0%
Model 5 0.7772 0.1135 0.3868 0.6211 0.7100 0.7891 0.8660 0.9138 0.9394 0%
Tobit model
Model 3 0.8005 0.1361 0.3414 0.6101 0.7127 0.8185 0.9032 0.9659 1.0203 2.5%
Model 4 0.8004 0.1372 0.3292 0.6057 0.7165 0.8153 0.9059 0.9653 1.0092 2.9%
Model 5 0.8004 0.1355 0.3341 0.6126 0.7224 0.8158 0.9059 0.9635 0.9949 0%
Censored least absolute deviation
Model 3 0.7761 0.1095 0.4044 0.6274 0.7102 0.7887 0.8573 0.9094 0.9531 0%
Model 4 0.7760 0.1119 0.3896 0.6188 0.7119 0.7879 0.8609 0.9099 0.9448 0%
Model 5 0.7743 0.1107 0.3965 0.6183 0.7070 0.7870 0.8602 0.9083 0.9326 0%
Quantile regression
Model 3 0.7761 0.1095 0.4044 0.6274 0.7102 0.7887 0.8573 0.9094 0.9531 0%
Model 4 0.7760 0.1119 0.3896 0.6188 0.7119 0.7879 0.8609 0.9099 0.9448 0%
Model 5 0.7743 0.1107 0.3965 0.6183 0.7070 0.7870 0.8602 0.9083 0.9326 0%
Logistic quantile regression
Model 3 0.7691 0.1042 0.3861 0.6221 0.7141 0.7936 0.8469 0.8804 0.9038 0%
Model 4 0.7680 0.1051 0.3780 0.6153 0.7146 0.7896 0.8463 0.8799 0.8971 0%
Model 5 0.7675 0.1085 0.3687 0.6093 0.7104 0.7914 0.8506 0.8817 0.8957 0%
Abbreviations: SD standard deviation, Min minimum, P10 10th percentile, Q1 1st quartile, Q3 third quartile, P90 90th percentile, Max maximum.
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index, but whether CLAD or OLS performed better, or
in what situation (e.g. proportion of patients attaining
full health) one method outperformed the other was in-
conclusive [28,30,31]. The OLS approach has some
merits that are not shared by other methods, such as
well-developed diagnostic checking techniques and its
availability in common statistical packages. In fact, as re-
ported in two recent reviews, OLS was the most com-
monly used method in mapping studies [4,32]. Both
reviews, however, were concerned by the quality of these
mapping algorithms using OLS. Hence, further research
on the usability of OLS in mapping studies is warranted.
Similar to our findings from the Japanese value set,
Austin et al. also obtained identical point estimates in
CLAD and quantile regression [22]. It has been pointed
out that Tobit and CLAD models should not be used for
analyzing health utility index because it is conceptually
bounded from above by 1, rather than censored at 1
[24]. In contrast, quantile regression recognizes the data
truly cannot exceed the upper boundary, as opposed to
assuming censoring at the boundary. Therefore, quantile
regression is conceptually more appropriate than Tobit
or CLAD. Logistic quantile regression, although not per-
forming well in the current study, has a theoreticaladvantage that the logistic transform can deal with the
boundary problem [26]. This not only suits the distribu-
tional property of health utility index, but also guaran-
tees the predicted values would not exceed the boundary
of 1.
The r2 values were no larger than 0.5 for all models
(Table 3), implying that at least half of the variance in
the data has not been accounted for. This moderate level
of accuracy is not uncommon in studies mapping FACT
instruments to EQ-5D utility index, e.g., R2 ranged from
0.317 to 0.451 for FACT-G [7], from 0.535 to 0.582 for
FACT-Prostate [8], and from 0.328 to 0.499 for FACT-
Melanoma [9]. On the other hand, the models were also
estimated in terms of the mean utility index in patients
with different level of performance status at follow-up.
Some of the differences between the mean observed and
predicted values within the same level were found statis-
tically significant. However, the differences were small
and less than the minimally important differences of
EQ-5D for cancer patients (0.08 for UK value set and
0.06 US value set) [33]. Thus we believed that the differ-
ences were clinically unimportant. Furthermore, the
mean predicted values showed a clear trend in relation to
the performance status, suggesting their good discrimin-
ating ability. Hence, the mapping algorithm appears to be
Table 5 Mean EQ-5D-5L utility index by patients’
self-assessed performance status at follow-up
Performance status P-value
for trendaModel 0 1 2 3 or 4
Observed data 0.8719 0.7273 0.5941 0.5941
Ordinary least square
Model 3 0.8518 0.7584** 0.6499 0.5886 < 0.001
Model 4 0.8537 0.7581** 0.6518 0.5883 < 0.001
Model 5 0.8560 0.7571** 0.6495 0.5842 < 0.001
Tobit model
Model 3 0.8890 0.7784** 0.6498 0.5772 < 0.001
Model 4 0.8913 0.7780** 0.6520 0.5768 < 0.001
Model 5 0.8944 0.7766** 0.6490 0.5710 < 0.001
Censored least absolute deviation
Model 3 0.8478* 0.7590** 0.6558 0.6004 < 0.001
Model 4 0.8512 0.7580** 0.6545 0.5948 < 0.001
Model 5 0.8505 0.7541** 0.6487 0.5829 < 0.001
Quantile regression
Model 3 0.8478* 0.7590** 0.6558 0.6004 < 0.001
Model 4 0.8512 0.7580** 0.6545 0.5948 < 0.001
Model 5 0.8505 0.7541** 0.6487 0.5829 < 0.001
Logistic quantile regression
Model 3 0.8341** 0.7548** 0.6526 0.5920 < 0.001
Model 4 0.8349** 0.7532** 0.6507 0.5886 < 0.001
Model 5 0.8387** 0.7508** 0.6422 0.5733 < 0.001
aCuzick’s nonparametric test for trend [29].
**P-value < 0.01; *P-value < 0.05 for signed-rank test between observed and
predicted utility index within the same performance status level.
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individual level.
We also tried mapping the individual items, instead of
subscales, of the FACT-B to EQ-5D-5L utility index
using OLS with stepwise selection. Although the model
using items as predictors obtained comparable r2, MSE
and MAD to that of Model 4 using OLS in Table 3, this
model resulted in a smaller adjusted r2 due to a larger
number of predictors, which implies a more complex
model. More importantly, in practice, missing values can
be imputed by the “half-rule” if subscales are being
mapped to utility index, but may not be properly han-
dled if individual items are used. Another possibility to
derive a FACT-B preference-based score is direct valu-
ation. However, unlike the EQ-5D that has only 5 items,
FACT-B has 37 items that makes direct valuation diffi-
cult due to the large number of possible health states.
Therefore, it is practically not feasible.
A limitation of this study is that the value set for the
5-level EQ-5D instrument was based on a crosswalk pro-
ject that linked the EQ-5D-3 L to the EQ-5D-5L [17].
Some recently published studies have reported the valueset of several Asian countries for EQ-5D-3 L but not for
EQ-5D-5L. The EQ-5D-5L value sets are best to be esti-
mated through direct valuation of the health states using
methods such as time trade-off. Nevertheless, this cross-
walk algorithm is currently the only available one for
converting the EQ-5D-5L responses to a utility index,
and the results are robust as indicated by a sensitivity
analysis using the UK value set. In fact, both Japan and
Singapore are highly modernized and their well-educated
populations are exposed to international influence. In a re-
view study of the development of HRQoL instruments in
Asian languages, Cheung and Thumboo found that QoL
concepts do not vary a lot with cultures, and items that
are highly specific to a society are uncommon [34].
Sakthong et al. compared the psychometric properties
among 3 value sets of the EQ-5D-3 L using a sample of in-
dividuals from Thailand, another south-east Asian coun-
try, and revealed that the Japanese value set obtained
better test-retest reliability, convergent validity and
known-group validity than the UK and US value sets [35].
Therefore, the use of the Japanese value set, though not
ideal, is expected to be appropriate for Singapore. That
said, our findings are best verified when there is a local
value set available in the future. Moreover, nearly 90% of
the patients in this study had a performance status of 0
to 1. This may limit the generalizability of the results to
more severe patients. Furthermore, instead of answering
both English and Chinese versions of the instruments, bi-
lingual subjects only selected the language they preferred
to use. This limited head-to-head comparison between
the language versions and assessment of equivalence.
That said, survey language was not significantly associ-
ated with the EQ-5D-5L utility index and did not im-
prove the goodness-of-fit nor qualitatively influence the
coefficient estimates of other independent variables, sug-
gesting that pooling the data from English and Chinese
versions for analysis is reasonable.
In conclusion, this study confirmed the feasibility of
mapping the FACT-B subscale scores to the EQ-5D-5L
utility index. Among the various regression methods
tested, OLS not only provided the best goodness-of-fit
measures, but also has the widest availability of statis-
tical packages for analysis and diagnostic checking.
Hence, we recommend OLS for mapping the FACT-B to
the EQ-5D-5L utility index. The findings are useful in
cost-utility and quality-adjusted life-year analyses for
breast cancer patients when only the FACT-B data are
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